{"id":751780,"date":"2023-04-26T19:29:49","date_gmt":"2023-04-26T23:29:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/"},"modified":"2023-04-26T19:29:49","modified_gmt":"2023-04-26T23:29:49","slug":"aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/","title":{"rendered":"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting"},"content":{"rendered":"
\n

HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, \u201cthe Company\u201d),\u00a0a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma was accepted for publication.<\/p>\n\n\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nPhase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)<\/td>\n<\/tr>\n
\n Presenter: <\/strong>\n <\/td>\nKathryn Beckermann, MD, PhD<\/td>\n<\/tr>\n
\n Abstract Number:<\/strong>\n <\/td>\n4534<\/td>\n<\/tr>\n
\n Format\/Session: <\/strong>\n <\/td>\nPoster; Genitourinary Cancer\u2014Kidney and Bladder<\/td>\n<\/tr>\n
\n Session Date\/Time: <\/strong>\n <\/td>\nSaturday, June 3, 2023, 8:00 AM \u2013 11:00 AM CDT<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nPhase 1b Batiraxcept (AVB-S6-500, BT) plus Gemcitabine (G) and Nab-paclitaxel (NP) as first-line treatment (1L) for pancreatic adenocarcinoma (PDAC)<\/td>\n<\/tr>\n
\n Abstract Number:<\/strong>\n <\/td>\ne16258<\/td>\n<\/tr>\n
\n Format\/Session: <\/strong>\n <\/td>\nPublication Only<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

The poster will be available on the \u201cPublications\u201d section of the Aravive website<\/a> when the ASCO embargo is released on May 25, 2023 at 4:00 PM CDT.<\/p>\n

\n About Aravive<\/strong>
\n
Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b\/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b\/2 trial in pancreatic adenocarcinoma (NCT04983407). The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Additional information at www.aravive.com<\/a>.<\/p>\n

\n Investor Relations Contact:<\/strong>\n <\/p>\n

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, \u201cthe Company\u201d),\u00a0a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma was accepted for publication. Title: Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC) Presenter: Kathryn Beckermann, MD, PhD Abstract Number: 4534 Format\/Session: … <\/p>\n

Continue reading “Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751780","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, \u201cthe Company\u201d),\u00a0a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma was accepted for publication. Title: Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC) Presenter: Kathryn Beckermann, MD, PhD Abstract Number: 4534 Format\/Session: … Continue reading "Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T23:29:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting\",\"datePublished\":\"2023-04-26T23:29:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/\",\"name\":\"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg=\",\"datePublished\":\"2023-04-26T23:29:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting - Market Newsdesk","og_description":"HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, \u201cthe Company\u201d),\u00a0a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma was accepted for publication. Title: Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC) Presenter: Kathryn Beckermann, MD, PhD Abstract Number: 4534 Format\/Session: … Continue reading \"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T23:29:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting","datePublished":"2023-04-26T23:29:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/"},"wordCount":357,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/","name":"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg=","datePublished":"2023-04-26T23:29:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjQ5NiM1NTYwMDA4IzIwMjcxOTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aravive-announces-poster-presentation-on-batiraxcept-at-2023-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751780"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751780\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}